Anton Rx Report

Catching up on a slew of FDA approvals in recent weeks….. whew! The FDA  recently approved a new therapy, Veopoz (pozelimab-bbfg) from Regeneron, for the treatment

Catching up on recent approvals….. Earlier this week we sent a Report on the approval of Talvey from Janssen Pharmaceuticals indicated for he treatment of

Catching up on recent approvals….. The FDA recently approved a new subcutaneous therapy, Talvey (talquetamab-tgvs) from Janssen Pharmaceutical (a J&J company) for the treatment of

Now here’s a two-fer for ya. First, there’s the news that another specialty pharmacy has been christened. Second, we learn what a group of zebras

When I was a kid going to Yankee Stadium for a baseball outing the hawkers selling programs would say…. “Ya can’t tell the players without a

Earlier this year the Pharmaceutical Strategies Group published a nifty report on trends in pharmacy benefits management. And, lo and behold, PSG has now doubled down

We sent a Report on compounding back in July. At that time we were alerting those pharmacies that engage in compounding that numerous new standards were

In recent weeks two leading specialty pharmacies announced their plans to strategically expand their footprint in the specialty pharmacy ambulatory infusion space. Curiously, that falls on

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely

Catching up on recent specialty approvals———— The FDA recently approved a new ORAL, kinase inhibitor therapy, Vanflyta (quizartinib) from Daiichi Sankyo Company, Ltd., in combination